Aloe‐Emodin Induces Breast Tumor Cell Apoptosis through Upregulation of miR‐15a/miR‐16‐1 That Suppresses BCL2

Xuefeng Jiang, Yusheng Liu, Guijuan Zhang, Shujun Lin, Jieyan Wu, Xianxin Yan, Yi Ma, Min MaEvidence-based 2020 · DOI

TL;DR

This study reveals that aloe-emodin, a natural compound, effectively induces apoptosis in breast tumor cells by upregulating specific microRNAs (miR-15a and miR-16-1). These microRNAs, in turn, suppress the expression of BCL2, a key protein involved in cell survival, ultimately leading to cancer cell death. This work offers a promising avenue for developing new breast cancer therapies.

What Problem Does This Paper Address?

Breast cancer (BC) remains a significant global health challenge, being the most frequently diagnosed malignancy in women and a leading cause of cancer-related deaths. Despite advances in diagnosis and treatment, there's a continuous need to understand the underlying molecular mechanisms driving BC and to identify novel therapeutic strategies. Specifically, this paper investigates the anti-cancer potential of aloe-emodin (AE), a natural compound derived from aloe vera, and aims to elucidate its mechanism of action in breast tumor cells, focusing on its effects on cell proliferation and apoptosis. The researchers are particularly interested in how AE might influence the Bcl-2 family of proteins, which are critical regulators of cell survival and death.

Methods

The study employed a multi-pronged approach to investigate the effects of aloe-emodin on breast tumor cells:

  • Cell Lines: Four human breast cell lines were used: MCF-10A (normal, non-tumorigenic), MCF-10AT (immortalized, non-tumorigenic), MCF-7 (ER-positive, luminal breast cancer), and MDA-MB-231 (triple-negative breast cancer). This selection allows for the comparison of AE's effects across different stages and subtypes of breast cancer.
  • Cell Proliferation Assay: The CCK-8 assay was utilized to quantify cell viability and proliferation after treatment with varying concentrations of AE over different time points (24, 48, and 72 hours).
  • Apoptosis Analysis: Flow cytometry, specifically using Annexin V-FITC/Propidium Iodide (PI) staining, was employed to measure the percentage of apoptotic cells.
  • Protein and mRNA Expression Analysis:
    • Western Blotting: This technique was used to assess the protein levels of key apoptosis regulators, including Bcl-2, Bcl-xl, and Bax, in response to AE treatment.
  • Quantitative Real-Time PCR (RT-PCR): This method was used to measure the mRNA levels of Bcl-2, Bcl-xl, and Bax, as well as the expression of specific microRNAs (miR-15a and miR-16-1).
  • Bioinformatics Analysis: Computational tools were used to predict potential binding sites of microRNAs on the 3'-UTR of Bcl-2 mRNA.
  • MicroRNA Mimics and Inhibitors: To confirm the role of specific microRNAs, cells were transfected with miR-15a/miR-16-1 mimics (to increase their levels) or inhibitors (to decrease their levels) to observe the downstream effects on Bcl-2 expression and cell viability.

Datasets

Not discussed in the paper. The study relies on established cell lines and experimental measurements rather than pre-existing datasets for training or evaluation.

Key Insights and Ideas

  • Selective Cytotoxicity of Aloe-Emodin: AE demonstrated a dose- and time-dependent inhibitory effect on the proliferation of MCF-10AT and MCF-7 cells, but had a significantly weaker effect on MCF-10A and MDA-MB-231 cells. This suggests AE might target specific pathways more prevalent in certain types of breast cancer cells.
  • AE Induces Apoptosis: AE treatment led to a significant increase in both early and late apoptotic cells in MCF-10AT and MCF-7 cell lines, indicating that AE promotes programmed cell death.
  • Modulation of Bcl-2 Family Proteins: AE treatment resulted in decreased protein expression of the anti-apoptotic proteins Bcl-2 and Bcl-xl, and increased expression of the pro-apoptotic protein Bax. This shift in the Bcl-2/Bax ratio is a hallmark of apoptosis induction.
  • Post-Transcriptional Regulation of Bcl-2: While AE altered Bcl-xl and Bax mRNA levels, it did not significantly affect Bcl-2 mRNA. This observation pointed towards a post-transcriptional mechanism, specifically involving microRNAs, in regulating Bcl-2 protein levels.
  • miR-15a/miR-16-1 as Key Mediators: Bioinformatics analysis identified miR-15a and miR-16-1 as potential regulators of Bcl-2. The study confirmed that AE upregulated these microRNAs, and importantly, that inhibiting miR-15a/16-1 could reverse the AE-induced inhibition of cell growth and the downregulation of Bcl-2 protein. This strongly implicates these microRNAs in AE's anti-cancer mechanism.

Key Results

  • AE inhibited the growth of MCF-10AT and MCF-7 cells with IC50 values of approximately 35.75 µM and 43.49 µM, respectively, at 72 hours.
  • Apoptosis rates in MCF-10AT cells increased from 2.33% (control) to 36.09% (40 µM AE), and in MCF-7 cells from 2.91% (control) to 22.58% (40 µM AE).
  • AE treatment led to a dose-dependent decrease in Bcl-2 and Bcl-xl protein levels and an increase in Bax protein levels in MCF-10AT and MCF-7 cells.
  • AE significantly upregulated the expression of miR-15a and miR-16-1 in a dose-dependent manner in both cell lines.
  • Inhibition of miR-15a/16-1 reversed the growth-inhibitory effects of AE and restored Bcl-2 protein levels, confirming their crucial role.

Limitations and Future Work

  • Mechanism of AE's effect on microRNA expression: The study acknowledges that the exact molecular mechanism by which AE alters miR-15a/16-1 expression remains unclear. It suggests that AE might influence transcription or indirectly affect microRNA levels through hormones or cytokines, which warrants further investigation.
  • In vivo studies: While the study provides strong in vitro evidence, future research should focus on validating these findings in animal models to assess the therapeutic potential of AE in a more complex biological system.
  • Broader applicability: The differential effects of AE on various cell lines suggest that further research is needed to understand its efficacy across a wider spectrum of breast cancer subtypes and to identify potential biomarkers for patient selection.
  • Combination therapies: Exploring the synergistic effects of AE with existing breast cancer treatments could lead to more effective therapeutic strategies.

Summary updated

Abstract

Our research provides an important basis that AE induces BT cell apoptosis through upregulation of miR-15a/miR-16-1 that suppresses BCL2.
BibTeX
@inproceedings{jiang2020aloeemodin,
  author = {Xuefeng Jiang and Yusheng Liu and Guijuan Zhang and Shujun Lin and Jieyan Wu and Xianxin Yan and Yi Ma and Min Ma},
  title = {{Aloe‐Emodin Induces Breast Tumor Cell Apoptosis through Upregulation of miR‐15a/miR‐16‐1 That Suppresses BCL2}},
  booktitle = {Evidence-based},
  year = {2020},
  doi = {10.1155/2020/5108298},
}
Figure